Literature DB >> 15894890

Correlation between left ventricular mass and urinary sodium excretion in specific genotypes of CYP11B2.

Mako Isaji1, Tomoatsu Mune, Nobuki Takada, Yoritsuna Yamamoto, Tetsuya Suwa, Hiroyuki Morita, Jun Takeda, Perrin C White.   

Abstract

BACKGROUND: Aldosterone has essential roles in regulating intravascular volume and blood pressure, and is suggested to influence cardiac structure. However, the association of polymorphisms in the aldosterone synthase gene (CYP11B2) with hypertension or cardiac hypertrophy remains controversial.
OBJECTIVE: To evaluate the distribution of polymorphisms in the CYP11B2 gene and the possible associations between genotypes and blood pressure, urinary excretion of aldosterone or electrolytes and echocardiographic measurements, in a Japanese population. METHODS AND
RESULTS: We examined the association of two common diallelic polymorphisms within CYP11B2, one in the promoter -344T/C and the other an intron 2 gene conversion, with blood pressure, 24-h urinary excretion of aldosterone and electrolytes, and echocardiographic measurements, in a Japanese population. We confirmed significant linkage disequilibrium between these polymorphic loci and ethnic differences in frequency of the alleles. The -344C and -344T haplotypes apparently diverged before the intron conversion polymorphism was generated on the latter haplotype. Allele frequencies did not differ between 535 normotensive and 360 hypertensive individuals or between hypertensive individuals with higher and lower concentrations of renin. The only significant correlation was a positive correlation of left ventricular mass with 24-h urinary excretion of sodium, which occurred only in individuals with the -344CC genotype or the intron 2 conversion (-/-) genotype.
CONCLUSIONS: The -344CC or intron 2 conversion (-/-) genotype in CYP11B2 may be a risk factor for developing sodium-sensitive cardiac hypertrophy. Ethnic differences in the distribution of CYP11B2 genotypes combined with differences in salt intake might account for inconsistencies between previous reports.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15894890     DOI: 10.1097/01.hjh.0000170377.00591.7e

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  7 in total

Review 1.  High salt intake as a multifaceted cardiovascular disease: new support from cellular and molecular evidence.

Authors:  Marcelo Perim Baldo; Sérgio Lamêgo Rodrigues; José Geraldo Mill
Journal:  Heart Fail Rev       Date:  2015-07       Impact factor: 4.214

Review 2.  Arterial Hypertension, Atrial Fibrillation, and Hyperaldosteronism: The Triple Trouble.

Authors:  Teresa M Seccia; Brasilina Caroccia; Gail K Adler; Giuseppe Maiolino; Maurizio Cesari; Gian Paolo Rossi
Journal:  Hypertension       Date:  2017-04       Impact factor: 10.190

3.  The renin-angiotensin-aldosterone system in cerebral small vessel disease.

Authors:  David Brenner; Julien Labreuche; Fernando Pico; Philip Scheltens; Odette Poirier; François Cambien; Pierre Amarenco
Journal:  J Neurol       Date:  2008-05-02       Impact factor: 4.849

Review 4.  Aldosterone and arterial hypertension.

Authors:  Andreas Tomaschitz; Stefan Pilz; Eberhard Ritz; Barbara Obermayer-Pietsch; Thomas R Pieber
Journal:  Nat Rev Endocrinol       Date:  2009-12-22       Impact factor: 43.330

5.  Aldosterone Synthase Promoter Polymorphism and Cardiovascular Phenotypes in a Large, Multiethnic Population-Based Study.

Authors:  James Brian Byrd; Richard J Auchus; Perrin C White
Journal:  J Investig Med       Date:  2015-10       Impact factor: 2.895

6.  Predictors of successful outcome after adrenalectomy for primary aldosteronism.

Authors:  Wei Wang; WeiLie Hu; XiaoMing Zhang; BangQi Wang; Chen Bin; Hai Huang
Journal:  Int Surg       Date:  2012 Apr-Jun

7.  The relationship among cardiac structure, dietary salt and aldosterone in patients with primary aldosteronism.

Authors:  Chi-Sheng Hung; Xue-Ming Wu; Ching-Way Chen; Ying-Hsien Chen; Vin-Cent Wu; Che-Wei Liao; Yi-Yao Chang; Ruh-Fang Yen; Ching-Chu Lu; Mao-Yuan M Su; Kao-Lang Liu; Chin-Chen Chang; Li-Yu Daisy Liu; Kwan-Dun Wu; Yen-Hung Lin
Journal:  Oncotarget       Date:  2017-04-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.